CN105412242A - 一种治疗炎症性肠病的组方 - Google Patents
一种治疗炎症性肠病的组方 Download PDFInfo
- Publication number
- CN105412242A CN105412242A CN201510937180.0A CN201510937180A CN105412242A CN 105412242 A CN105412242 A CN 105412242A CN 201510937180 A CN201510937180 A CN 201510937180A CN 105412242 A CN105412242 A CN 105412242A
- Authority
- CN
- China
- Prior art keywords
- intestinal
- composition
- inflammatory bowel
- oxygen
- glutamine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000022559 Inflammatory bowel disease Diseases 0.000 title abstract description 5
- 239000000203 mixture Substances 0.000 title abstract 6
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims abstract description 13
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims abstract description 12
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000004473 Threonine Substances 0.000 claims abstract description 12
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims abstract description 12
- 235000018417 cysteine Nutrition 0.000 claims abstract description 12
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims abstract description 11
- 235000013734 beta-carotene Nutrition 0.000 claims abstract description 11
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims abstract description 11
- 239000011648 beta-carotene Substances 0.000 claims abstract description 11
- 229960002747 betacarotene Drugs 0.000 claims abstract description 11
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims abstract description 11
- 235000019155 vitamin A Nutrition 0.000 claims abstract description 9
- 239000011719 vitamin A Substances 0.000 claims abstract description 9
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 6
- 239000011718 vitamin C Substances 0.000 claims abstract description 6
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 6
- 239000011709 vitamin E Substances 0.000 claims abstract description 6
- 230000002757 inflammatory effect Effects 0.000 claims description 11
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 8
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 7
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 7
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 7
- 229940045997 vitamin a Drugs 0.000 claims description 7
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 4
- 229930003268 Vitamin C Natural products 0.000 claims description 4
- 229930003427 Vitamin E Natural products 0.000 claims description 4
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 4
- 229940046009 vitamin E Drugs 0.000 claims description 4
- 230000000968 intestinal effect Effects 0.000 abstract description 28
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 19
- 239000001301 oxygen Substances 0.000 abstract description 19
- 229910052760 oxygen Inorganic materials 0.000 abstract description 19
- 210000001519 tissue Anatomy 0.000 abstract description 17
- 230000004888 barrier function Effects 0.000 abstract description 15
- 206010061218 Inflammation Diseases 0.000 abstract description 11
- 210000002175 goblet cell Anatomy 0.000 abstract description 11
- 230000004054 inflammatory process Effects 0.000 abstract description 11
- 230000000694 effects Effects 0.000 abstract description 10
- 239000003814 drug Substances 0.000 abstract description 8
- 102000001621 Mucoproteins Human genes 0.000 abstract description 7
- 108010093825 Mucoproteins Proteins 0.000 abstract description 7
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 abstract description 5
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 abstract description 5
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 abstract description 4
- 230000036770 blood supply Effects 0.000 abstract description 4
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract description 3
- 210000004347 intestinal mucosa Anatomy 0.000 abstract description 3
- 239000002994 raw material Substances 0.000 abstract description 3
- 235000015097 nutrients Nutrition 0.000 abstract description 2
- 230000028327 secretion Effects 0.000 abstract description 2
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 abstract 2
- 241000304195 Salvia miltiorrhiza Species 0.000 abstract 2
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 235000004554 glutamine Nutrition 0.000 abstract 1
- 210000005260 human cell Anatomy 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 235000004400 serine Nutrition 0.000 abstract 1
- 235000008521 threonine Nutrition 0.000 abstract 1
- 239000000427 antigen Substances 0.000 description 18
- 102000036639 antigens Human genes 0.000 description 18
- 108091007433 antigens Proteins 0.000 description 18
- 210000001035 gastrointestinal tract Anatomy 0.000 description 18
- 201000010099 disease Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 7
- 229940088594 vitamin Drugs 0.000 description 7
- 229930003231 vitamin Natural products 0.000 description 7
- 235000013343 vitamin Nutrition 0.000 description 7
- 239000011782 vitamin Substances 0.000 description 7
- 150000003722 vitamin derivatives Chemical class 0.000 description 7
- 230000002159 abnormal effect Effects 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 230000007812 deficiency Effects 0.000 description 6
- 230000003203 everyday effect Effects 0.000 description 6
- 230000001717 pathogenic effect Effects 0.000 description 6
- 210000000987 immune system Anatomy 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 3
- 210000000981 epithelium Anatomy 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 230000033289 adaptive immune response Effects 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000015788 innate immune response Effects 0.000 description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 244000000010 microbial pathogen Species 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 102000007863 pattern recognition receptors Human genes 0.000 description 2
- 108010089193 pattern recognition receptors Proteins 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 101150063569 slgA gene Proteins 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010070545 Bacterial translocation Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010012742 Diarrhoea infectious Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 101710146739 Enterotoxin Proteins 0.000 description 1
- 206010015084 Episcleritis Diseases 0.000 description 1
- 206010015226 Erythema nodosum Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 206010028034 Mouth ulceration Diseases 0.000 description 1
- 241000269799 Perca fluviatilis Species 0.000 description 1
- 241000269800 Percidae Species 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 206010039705 Scleritis Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000002052 anaphylactic effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000007375 bacterial translocation Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000000147 enterotoxin Substances 0.000 description 1
- 231100000655 enterotoxin Toxicity 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 230000003870 intestinal permeability Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- -1 monoclonal antibody Substances 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 150000002926 oxygen Chemical class 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000009954 pyoderma gangrenosum Diseases 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Zoology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明公开了一种治疗炎症性肠病的组方,属药品领域。本发明以丹参、谷氨酰胺、苏氨酸、丝氨酸、半胱氨酸、维生素C、E、A和β-胡萝卜素为组方。丹参有增强人体血液供应和氧气供应的功效;谷氨酰胺是肠黏膜主要能量来源;苏氨酸、丝氨酸、半胱氨酸是黏蛋白的主要组成部分;维生素C、E、A和β-胡萝卜素有阻抑氧自由基活性、清除氧自由基、保护人体细胞的作用。本发明组方为杯状细胞的发生、更新、修复及杯状细胞分泌黏蛋白组成肠道表面黏液层屏障提供营养、氧气和原料。本发明组方对终止炎症、修复肠道组织、构建人体正常的肠道表面黏液层屏障效果明显,是治疗炎症性肠病的有效组方。
Description
技术领域
本发明涉及治疗炎症性肠病的中药材与氨基酸、维生素的组合配方,属于药品领域。
背景技术
炎症性肠病(inflammatoryboweldisease,IBD)是一种发病原因和发病机制尚未完全明确的疾病。因发病原因和发病机制尚未完全阐明,故人们不能从根本上来阻止或者延缓该疾病病程的进展。
医学免疫学认为,免疫系统对抗原识别与耐受发生异常,即对肠道正常栖息微生物非正常识别产生免疫应答,引发该病。组织学与胚胎学则认为,肠黏膜通透性过高,导致大量肠道抗原进入肠壁组织,引发了免疫系统长久的应答反应引发该疾病。
目前对炎症性肠病的治疗以医学免疫学为主导,主要治疗措施是干预、抑制免疫应答和炎症对肠道的损伤,如使用糖皮质激素、氨基水杨酸制剂、单克隆抗体、免疫抑制剂等。上述治疗措施效果不理想并且副作用大,所以,对炎症性肠病病因的研究,找到发病原因,采取相应的治疗措施是医学界刻不容缓的任务。
发明内容
本发明以现代医学为基础,在探究炎症性肠病发病原因的基础上提出自己的治疗措施,即增援肠道组织和上皮杯状细胞,构建正常的肠道表面黏液层屏障,阻止肠道抗原接近、接触、粘附和进入肠壁组织,从而阻断异常免疫应答的发生,同时终止炎症、修复受损伤的肠壁组织。
如果说,对已经发生的免疫应答及炎症进行干预是扬汤止沸,那么本发明的组方治疗措施是釜底抽薪。
人体的肠道黏膜屏障首先是肠道表面黏液层屏障,肠道表面黏液层屏障是肠道黏膜屏障的第一道防线。肠道表面黏液层是由肠道上皮杯状细胞分泌的黏蛋白组成。正常的肠道表面黏液层的功能是阻止肠道内的微生物包括病原微生物、正常栖息微生物和食源性抗原接近、接触、粘附和进入肠道上皮即肠道壁,而对于“企图”穿越表面黏液层的微生物特别是病原微生物发挥粘附与包裹的作用,避免异常免疫应答和炎症的发生。
肠道黏液层屏障会有一定的波动,导致少量的微生物性抗原或食源性抗原穿越肠道表面黏液层,接近、接触、粘附和进入肠道上皮。这些穿越肠道表面黏液层的抗原首先被固有免疫系统的模式识别受体(PRRs)所识别并引发固有免疫应答以清除抗原。
当固有免疫应答不能清除抗原时,抗原会被抗原提呈细胞(APC)如巨噬细胞(Μφ)、树突状细胞(DC)等摄取、提呈而引发适应性免疫应答。适应性免疫应答在清除进入肠道组织的抗原过程中免疫系统会向肠腔释放大量的分泌性免疫球蛋白A(secretorylffA,slgA)。slgA释人肠腔后可特异性地与抗原结合,抑制或杀灭细菌,中和病毒,防止抗原接近、接触、粘附和进入肠上皮,从而达到免疫平衡。
肠道表面黏液层屏障的失调导致肠道抗原大量接近、接触、粘附和粘附、进入肠壁,免疫系统无法及时清除抗原,从而免疫平衡被打破,引发异常免疫应答和炎症,损伤肠道组织,这是炎症性肠病的发病原因。
肠道表面黏液层屏障失调的原因可能是杯状细胞非正常状态的表现,包括杯状细胞的缺损、不足及更新、功能障碍;也可能是杯状细胞分泌黏蛋白障碍。杯状细胞非正常状态和杯状细胞分泌黏蛋白障碍的主要原因是肠道供血供氧不足或并有蛋白质性营养不良造成肠道细胞代谢底物不足、合成黏蛋白的原料不足等。
本发明的内容,是中药材丹参与谷氨酰胺、苏氨酸、丝氨酸、半胱氨酸、维生素C、E、A和β-胡萝卜素的组合配方。
丹参有增强人体血液供应和氧气供应的功效。
人体的氧气储备相对于营养素储备来说极为微少,当人体有超量耗氧需求时可能会因氧气供应不足而对人体造成损伤,故人体在疾病状态时增加氧气供应尤为重要。
谷氨酰胺是肠黏膜主要能量来源。谷氨酰胺能促进氮平衡,保持肠黏膜完整,防止细菌易位和肠道毒素进入血液。苏氨酸、丝氨酸、半胱氨酸是杯状细胞分泌黏蛋白的主要原料。
应用本发明丹参与谷氨酰胺、苏氨酸、丝氨酸、半胱氨酸的组方,能增强肠道组织血液供应和氧气供应,为杯状细胞的发生、修复、更新和正常工作提供充足的营养和氧气,为杯状细胞分泌黏蛋白提供充足的原料和氧气,从而构建正常的肠道表面黏液层屏障,阻止肠道抗原接近、接触、粘附和进入到肠道组织,阻止异常免疫应答的发生,进而达到炎症的终止和肠道组织的修复,这就是本发明组方治疗炎症性肠病的作用机制。
病理学资料显示,白细胞杀伤、降解病原体、抗原、组织碎片需要消耗比正常时多2~20倍的氧气,所以,炎症性肠病病人增强炎症部位的氧气供应对炎症的效率和炎症的终止具有极其重要的意义。
人体在炎症状态下会产生大量的氧自由基,氧自由基会对机体造成损伤,影响炎症的终止和组织的修复。
本发明应用丹参能增强肠道组织的氧气供应,从而加快肠道组织中抗原的清除,加快肠道组织细胞的发生、修复、更新进程,同时也会产生更多的氧自由基。维生素C、E、A和β-胡萝卜素有阻抑氧自由基活性、清除氧自由基、保护人体细胞的作用,所以炎症性肠病病人在服用丹参的同时补充这些维生素对肠道炎症的终止和组织的修复尤其必要。
本发明所述的丹参是《中华人民共和国药典》规定的丹参,具体实施方式中的用量是以干燥的根及根茎原药计量。
本发明的配方可以制作成咀嚼剂、含剂和口服剂,以咀嚼剂、含剂效果最好。
根据医学免疫学的黏膜免疫系统(mucosalimmunesystem)、黏膜移行系统(mucosalmigrationsystem,MMS)和“免疫巡检”理论,肠道表面黏液层屏障失调还可以引发诸如外周关节炎、结节性红斑、坏疽性脓皮病、巩膜外层炎、复发性口腔溃疡等疾病;肠道表面黏液层屏障失调还可能引发自身免疫性疾病、风湿病和过敏性疾病。探究肠道表面黏液层屏障与疾病的关系将是21世纪基础医学的重要研究领域。构建正常的肠道表面黏液层屏障,修复受损伤的肠道组织是本发明的重要内容,是本发明配方的主要功效。
大量的实践证明,应用本发明的组方治疗肠易激综合征、感染性腹泻、不明原因的长期腹泻、哮喘、过敏性鼻炎有可靠的效果。
根据中西医结合的理论,人体的疾病大多源于气虚血虚,本发明的配方能增强人体整体的血液供应和氧气供应,所以对气虚血虚的人有很好的治疗作用。
按照健康美丽长寿增援说,人体的疾病、衰老大都与机体缺血缺氧有关,解决机体缺血缺氧问题,大部分疾病可以预防和治疗,人类寿命可以大幅度延长。
具体实施方式
一、丹参0.6克、谷氨酰胺1.2克、苏氨酸0.5克、丝氨酸0.6克、半胱氨酸0.06克、维生素C50毫克、维生素E4毫克、维生素A0.1毫克、β-胡萝卜素0.6毫克制作成咀嚼剂,每天2到4次。
二、丹参0.3克、谷氨酰胺0.6克、苏氨酸0.25克、丝氨酸0.3克、半胱氨酸0.03克、维生素C25毫克、维生素E2毫克、维生素A0.05毫克、β-胡萝卜素0.3毫克制作成咀嚼剂,每天2到4次。
三、丹参0.6克、谷氨酰胺1.2克、苏氨酸0.5克、丝氨酸0.6克、半胱氨酸0.06克、维生素C50毫克、维生素E4毫克、维生素A0.1毫克、β-胡萝卜素0.6毫克制作成含剂,每天2到4次。
四、丹参0.3克、谷氨酰胺0.6克、苏氨酸0.25克、丝氨酸0.3克、半胱氨酸0.03克、维生素C25毫克、维生素E2毫克、维生素A0.05毫克、β-胡萝卜素0.3毫克制作成含剂,每天2到4次。
五、丹参6克、谷氨酰胺1.2克、苏氨酸0.5克、丝氨酸0.6克、半胱氨酸0.06克、维生素C50毫克、维生素E4毫克、维生素A0.1毫克、β-胡萝卜素0.6毫克制作成口服剂,每天2到4次。
六、丹参3克、谷氨酰胺0.6克、苏氨酸0.25克、丝氨酸0.3克、半胱氨酸0.03克、维生素C25毫克、维生素E2毫克、维生素A0.05毫克、β-胡萝卜素0.3毫克制作成口服剂,每天2到4次。
Claims (1)
1.一种治疗炎症性肠病的组方,其组方特征为:丹参6~60份、谷氨酰胺12份、苏氨酸5份、丝氨酸6份、半胱氨酸0.6份、维生素C0.5份、维生素E0.04份、维生素A0.001份、β-胡萝卜素0.006份。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510937180.0A CN105412242A (zh) | 2015-12-16 | 2015-12-16 | 一种治疗炎症性肠病的组方 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510937180.0A CN105412242A (zh) | 2015-12-16 | 2015-12-16 | 一种治疗炎症性肠病的组方 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105412242A true CN105412242A (zh) | 2016-03-23 |
Family
ID=55491091
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510937180.0A Pending CN105412242A (zh) | 2015-12-16 | 2015-12-16 | 一种治疗炎症性肠病的组方 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105412242A (zh) |
-
2015
- 2015-12-16 CN CN201510937180.0A patent/CN105412242A/zh active Pending
Non-Patent Citations (3)
Title |
---|
中华医学会: "维生素矿物质补充剂在炎症性肠病防治中的临床应用:专家共识", 《中华临床营养杂志》 * |
孙菁 译: "炎症性肠病中的黏膜愈合:"营养支持"有无一席之地?", 《INFLAMMATORY BOWEL DISEASES》 * |
齐玲芝等: "丹参辅助治疗溃疡性结肠炎的临床分析", 《吉林中医药》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105362338A (zh) | 一种治疗炎症性肠病的组方 | |
CN105434524A (zh) | 一种治疗炎症性肠病的组方 | |
CN105362306A (zh) | 一种治疗炎症性肠病的组方 | |
CN105343172A (zh) | 一种治疗炎症性肠病的组方 | |
CN105412237A (zh) | 一种治疗炎症性肠病的组方 | |
CN105412157A (zh) | 一种治疗炎症性肠病的组方 | |
CN105412242A (zh) | 一种治疗炎症性肠病的组方 | |
CN105412159A (zh) | 一种治疗炎症性肠病的组方 | |
CN105412233A (zh) | 一种治疗炎症性肠病的组合配方 | |
CN105477063A (zh) | 一种治疗炎症性肠病的组合配方 | |
CN105395605A (zh) | 一种治疗炎症性肠病的组方之十一 | |
CN105412190A (zh) | 一种治疗炎症性肠病的组合配方 | |
CN105477061A (zh) | 一种治疗炎症性肠病的组合配方 | |
CN105477060A (zh) | 一种治疗炎症性肠病的组方 | |
CN105412166A (zh) | 一种治疗炎症性肠病的组方 | |
CN105412235A (zh) | 一种治疗炎症性肠病的组合配方 | |
CN105456319A (zh) | 一种治疗炎症性肠病的组方 | |
CN105412234A (zh) | 一种治疗炎症性肠病的组合配方 | |
CN105477062A (zh) | 一种治疗炎症性肠病的组方 | |
CN105456356A (zh) | 一种治疗炎症性肠病的组合配方 | |
CN105456354A (zh) | 一种治疗炎症性肠病的组方 | |
CN105456318A (zh) | 一种治疗炎症性肠病的组方 | |
CN105412163A (zh) | 一种治疗炎症性肠病的组合配方 | |
CN105362305A (zh) | 一种治疗炎症性肠病的组方 | |
CN105434522A (zh) | 一种治疗炎症性肠病的组方 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160323 |
|
RJ01 | Rejection of invention patent application after publication |